The Experts below are selected from a list of 23907 Experts worldwide ranked by ideXlab platform
Luis F. Porrata - One of the best experts on this subject based on the ideXlab platform.
-
The prognostic role of the preoperative absolute Lymphocyte Count and absolute monocyte Count in patients with resected advanced melanoma.
American journal of clinical oncology, 2015Co-Authors: Nicole M. Rochet, Lisa A. Kottschade, Travis E. Grotz, Luis F. Porrata, Svetomir N. MarkovicAbstract:Objectives:Published data have reported that components of the peripheral blood are significant prognostic factors in hematologic and solid malignancies. Thus, we sought to investigate if the preoperative absolute Lymphocyte Count (ALC) and absolute monocyte Count (AMC) affects disease progression a
-
host immunity affects survival in myelodysplastic syndromes independent prognostic value of the absolute Lymphocyte Count
American Journal of Hematology, 2010Co-Authors: Nisha L Jacobs, Luis F. Porrata, Svetomir N. Markovic, Ayalew Tefferi, Shernan G Holtan, David P SteensmaAbstract:The prognostic significance of the peripheral blood absolute Lymphocyte Count (ALC) has been carefully examined in lymphoid malignancies, but the importance of the baseline ALC in chronic myeloid neoplasms is less clear. In a recent analysis of myelodysplastic syndromes (MDS) associated with deletion of chromosome 5q, we observed that an ALC < 1.2× 109 cells/L at diagnosis is independently associated with poorer survival. Clinicopathological data from 503 patients with non-del(5q) MDS evaluated at Mayo Clinic between 1996 and 2007 were reviewed to determine the prognostic impact of ALC at diagnosis in non-del(5q) MDS. Patients with MDS and an ALC at diagnosis ≥1.2× 109 (N = 248) experienced a superior overall survival (OS) compared with patients with an ALC < 1.2× 109/L (N = 255, median OS of 26.6 months versus 18.5 months, P < 0.001, respectively). ALC at diagnosis was an independent predictor for OS when compared with the International Prognostic Scoring System and the WHO-based Prognostic Scoring System. This study suggests that ALC at diagnosis is a prognostic factor for OS in MDS, and argues in favor of further studies to assess the role of host immunity in MDS clinical outcomes. Am. J. Hematol. 2010. © 2009 Wiley-Liss, Inc.
-
prediction of survival using absolute Lymphocyte Count for newly diagnosed patients with multiple myeloma a retrospective study
British Journal of Haematology, 2008Co-Authors: Hilmi Ege, Svetomir N. Markovic, Morie A Gertz, Martha Q Lacy, Angela Dispenzieri, Suzanne R Hayman, Shaji Kumar, Luis F. PorrataAbstract:Absolute Lymphocyte Count (ALC) recovery after autologous stem cell transplantation for multiple myeloma (MM) has been reported to be an independent prognostic factor for clinical outcome. The role of ALC on survival in newly diagnosed untreated MM patients is unknown. Between 1994 and 2002, we analysed retrospectively 537 MM patients of 1835 consecutive MM patients that were neither uniformly treated nor part of a clinical trail, but originally diagnosed and followed at the Mayo Clinic. The primary endpoint was to assess the role of ALC at the time of MM diagnosis on overall survival (OS). The median follow-up was 35.1 months (range: 1-152.5 months). ALC, as a continuous variable, was identified as prognostic factor for OS (Hazard ratio = 0.473, 95% confidence interval = 0.359-0.618, P /=1.4 x 10(9)/l experienced superior OS compared with MM patients with an ALC <1.4 x 10(9)/l (65 vs. 26 months, P < 0.0001). Multivariate analysis identified ALC as an independent prognostic factor for OS. This study showed that, in newly diagnosed MM, ALC is an independent prognostic factor for OS, suggesting a significant role of host immune status in the survival of MM.
-
absolute Lymphocyte Count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia
Leukemia, 2006Co-Authors: D Behl, Luis F. Porrata, Svetomir N. Markovic, Louis Letendre, R K Pruthi, C C Hook, Ayalew Tefferi, Mary Elliot, Scott H Kaufmann, Ruben A MesaAbstract:Absolute Lymphocyte Count (ALC) recovery postautologous stem cell transplantation is an independent predictor for survival in acute myelogenous leukemia (AML). The role of ALC recovery after induction chemotherapy (IC) in AML is unknown. We hypothesize that ALC recovery after IC has a direct impact on survival. We have now evaluated the impact of ALC recovery after IC on overall survival (OS) and leukemia-free survival (LFS) in 103 consecutive, newly diagnosed AML patients treated with standard IC and consolidation chemotherapy (CC) from 1998 to 2002. ALC recovery was studied at days 15 (ALC-15), 21 (ALC-21), 28 (ALC-28) after IC and before the first CC (ALC-CC). Superior OS and LFS at each time point were observed with an ALC-15, ALC-21, ALC-28, and ALC-CC > or = 500 cells/microl. Patients with an ALC > or = 500 cells/microl at all time points vs those who did not have superior OS and LFS (not reached vs 13 months, P or = 500 cells/microl at all time points to be an independent prognostic factor for survival. Our data suggest a critical role of Lymphocyte (immune) recovery on survival after IC in AML.
-
infused peripheral blood autograft absolute Lymphocyte Count correlates with day 15 absolute Lymphocyte Count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non hodgkin s lymphoma
Bone Marrow Transplantation, 2004Co-Authors: Luis F. Porrata, David J Inwards, Mark R Litzow, Dennis A Gastineau, S B Moore, Alvaro A Pineda, Kevin L Bundy, Douglas J Padley, Daniel O Persky, S M AnsellAbstract:Absolute Lymphocyte Count at day 15 (ALC-15) after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT) is an independent prognostic factor for survival in non-Hodgkin's lymphoma (NHL). Factors affecting ALC-15 remain unknown. We hypothesized that dose of infused autograft Lymphocytes (A-ALC) directly impacts upon ALC-15. A total of 190 consecutive NHL patients received A-ALC between 1993 and 2001. The primary end point was correlation between A-ALC and ALC-15. A strong correlation was identified (r=0.71). A higher A-ALC was infused into patients achieving an ALC-15 > or =500/microl vs ALC-15 /=0.5 x 10(9)/kg vs A-ALC <0.5 x 10(9)/kg (76 vs 17 months, P<0.0001; 49 vs 10 months, P<0.0001, respectively). Multivariate analysis demonstrated A-ALC to be an independent prognostic indicator for OS and PFS. These data support our hypothesis that ALC-15 and survival are dependent upon the dose of infused A-ALC in NHL.
Dale L Waldner - One of the best experts on this subject based on the ideXlab platform.
-
using peripheral smear review age and absolute Lymphocyte Count as predictors of abnormal peripheral blood lymphocytoses diagnosed by flow cytometry
Leukemia & Lymphoma, 2008Co-Authors: Jared M Andrews, Dan L Cruser, Jerome B Myers, Colby A Fernelius, Mitchel T Holm, Dale L WaldnerAbstract:Absolute lymphocytosis in the elderly raises the possibility of malignancy and generally warrants further investigation. To better correlate clinical variables with the frequency of neoplastic lymphoid processes in this population, we retrospectively reviewed archived flow cytometric analyses from peripheral blood specimens on patients of 50 years of age and older that had been deemed suspicious for a lymphoproliferative process after peripheral smear review. Age, absolute Lymphocyte Count (ALC), white blood cell Count and relative Lymphocyte Count were correlated with the results of flow cytometry. Of 71 total cases, 42 (59%) had an abnormal immunophenotype. Independent variables that showed significant differences between normal and abnormal immunophenotype were mean age (p = 0.001) and ALC (p = 0.0032). We combined age and absolute Lymphocyte Count variables to look for the best possible cutoff values to predict the likelihood of an abnormal immunophenotype. ALC cutoff values of ≥4 × 109 cells/L for pa...
-
using peripheral smear review age and absolute Lymphocyte Count as predictors of abnormal peripheral blood lymphocytoses diagnosed by flow cytometry
Leukemia & Lymphoma, 2008Co-Authors: Jared M Andrews, Dan L Cruser, Jerome B Myers, Colby A Fernelius, Mitchel T Holm, Dale L WaldnerAbstract:Absolute lymphocytosis in the elderly raises the possibility of malignancy and generally warrants further investigation. To better correlate clinical variables with the frequency of neoplastic lymphoid processes in this population, we retrospectively reviewed archived flow cytometric analyses from peripheral blood specimens on patients of 50 years of age and older that had been deemed suspicious for a lymphoproliferative process after peripheral smear review. Age, absolute Lymphocyte Count (ALC), white blood cell Count and relative Lymphocyte Count were correlated with the results of flow cytometry. Of 71 total cases, 42 (59%) had an abnormal immunophenotype. Independent variables that showed significant differences between normal and abnormal immunophenotype were mean age (p = 0.001) and ALC (p = 0.0032). We combined age and absolute Lymphocyte Count variables to look for the best possible cutoff values to predict the likelihood of an abnormal immunophenotype. ALC cutoff values of >or=4 x 10(9) cells/L for patients over 67 years of age, and >6.7 x 10(9) cells/L for patients between 50 and 67 years of age, had a high sensitivity for detecting an abnormal immunophenotype.
S M Ansell - One of the best experts on this subject based on the ideXlab platform.
-
infused peripheral blood autograft absolute Lymphocyte Count correlates with day 15 absolute Lymphocyte Count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non hodgkin s lymphoma
Bone Marrow Transplantation, 2004Co-Authors: Luis F. Porrata, David J Inwards, Mark R Litzow, Dennis A Gastineau, S B Moore, Alvaro A Pineda, Kevin L Bundy, Douglas J Padley, Daniel O Persky, S M AnsellAbstract:Absolute Lymphocyte Count at day 15 (ALC-15) after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT) is an independent prognostic factor for survival in non-Hodgkin's lymphoma (NHL). Factors affecting ALC-15 remain unknown. We hypothesized that dose of infused autograft Lymphocytes (A-ALC) directly impacts upon ALC-15. A total of 190 consecutive NHL patients received A-ALC between 1993 and 2001. The primary end point was correlation between A-ALC and ALC-15. A strong correlation was identified (r=0.71). A higher A-ALC was infused into patients achieving an ALC-15 > or =500/microl vs ALC-15 /=0.5 x 10(9)/kg vs A-ALC <0.5 x 10(9)/kg (76 vs 17 months, P<0.0001; 49 vs 10 months, P<0.0001, respectively). Multivariate analysis demonstrated A-ALC to be an independent prognostic indicator for OS and PFS. These data support our hypothesis that ALC-15 and survival are dependent upon the dose of infused A-ALC in NHL.
-
infused peripheral blood autograft absolute Lymphocyte Count correlates with day 15 absolute Lymphocyte Count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non hodgkin s lymphoma
Bone Marrow Transplantation, 2004Co-Authors: Luis F. Porrata, David J Inwards, Mark R Litzow, Dennis A Gastineau, S B Moore, Alvaro A Pineda, Kevin L Bundy, Douglas J Padley, D Persky, S M AnsellAbstract:Absolute Lymphocyte Count at day 15 (ALC-15) after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT) is an independent prognostic factor for survival in non-Hodgkin's lymphoma (NHL). Factors affecting ALC-15 remain unknown. We hypothesized that dose of infused autograft Lymphocytes (A-ALC) directly impacts upon ALC-15. A total of 190 consecutive NHL patients received A-ALC between 1993 and 2001. The primary end point was correlation between A-ALC and ALC-15. A strong correlation was identified (r=0.71). A higher A-ALC was infused into patients achieving an ALC-15 ⩾500/μl vs ALC-15 <500/μl (median of 0.68 × 109/kg (0.04–2.21 × 109/kg), vs 0.34 × 109/kg (0.04–1.42 × 109/kg), P<0.0001). The median follow-up for all patients was 36 months (maximum of 109 months). The A-ALC threshold was determined at 0.5 × 109/kg. The median overall survival (OS) and progression-free survival (PFS) times were longer in patients who received an A-ALC ⩾0.5 × 109/kg vs A-ALC <0.5 × 109/kg (76 vs 17 months, P<0.0001; 49 vs 10 months, P<0.0001, respectively). Multivariate analysis demonstrated A-ALC to be an independent prognostic indicator for OS and PFS. These data support our hypothesis that ALC-15 and survival are dependent upon the dose of infused A-ALC in NHL.
Svetomir N. Markovic - One of the best experts on this subject based on the ideXlab platform.
-
The prognostic role of the preoperative absolute Lymphocyte Count and absolute monocyte Count in patients with resected advanced melanoma.
American journal of clinical oncology, 2015Co-Authors: Nicole M. Rochet, Lisa A. Kottschade, Travis E. Grotz, Luis F. Porrata, Svetomir N. MarkovicAbstract:Objectives:Published data have reported that components of the peripheral blood are significant prognostic factors in hematologic and solid malignancies. Thus, we sought to investigate if the preoperative absolute Lymphocyte Count (ALC) and absolute monocyte Count (AMC) affects disease progression a
-
host immunity affects survival in myelodysplastic syndromes independent prognostic value of the absolute Lymphocyte Count
American Journal of Hematology, 2010Co-Authors: Nisha L Jacobs, Luis F. Porrata, Svetomir N. Markovic, Ayalew Tefferi, Shernan G Holtan, David P SteensmaAbstract:The prognostic significance of the peripheral blood absolute Lymphocyte Count (ALC) has been carefully examined in lymphoid malignancies, but the importance of the baseline ALC in chronic myeloid neoplasms is less clear. In a recent analysis of myelodysplastic syndromes (MDS) associated with deletion of chromosome 5q, we observed that an ALC < 1.2× 109 cells/L at diagnosis is independently associated with poorer survival. Clinicopathological data from 503 patients with non-del(5q) MDS evaluated at Mayo Clinic between 1996 and 2007 were reviewed to determine the prognostic impact of ALC at diagnosis in non-del(5q) MDS. Patients with MDS and an ALC at diagnosis ≥1.2× 109 (N = 248) experienced a superior overall survival (OS) compared with patients with an ALC < 1.2× 109/L (N = 255, median OS of 26.6 months versus 18.5 months, P < 0.001, respectively). ALC at diagnosis was an independent predictor for OS when compared with the International Prognostic Scoring System and the WHO-based Prognostic Scoring System. This study suggests that ALC at diagnosis is a prognostic factor for OS in MDS, and argues in favor of further studies to assess the role of host immunity in MDS clinical outcomes. Am. J. Hematol. 2010. © 2009 Wiley-Liss, Inc.
-
prediction of survival using absolute Lymphocyte Count for newly diagnosed patients with multiple myeloma a retrospective study
British Journal of Haematology, 2008Co-Authors: Hilmi Ege, Svetomir N. Markovic, Morie A Gertz, Martha Q Lacy, Angela Dispenzieri, Suzanne R Hayman, Shaji Kumar, Luis F. PorrataAbstract:Absolute Lymphocyte Count (ALC) recovery after autologous stem cell transplantation for multiple myeloma (MM) has been reported to be an independent prognostic factor for clinical outcome. The role of ALC on survival in newly diagnosed untreated MM patients is unknown. Between 1994 and 2002, we analysed retrospectively 537 MM patients of 1835 consecutive MM patients that were neither uniformly treated nor part of a clinical trail, but originally diagnosed and followed at the Mayo Clinic. The primary endpoint was to assess the role of ALC at the time of MM diagnosis on overall survival (OS). The median follow-up was 35.1 months (range: 1-152.5 months). ALC, as a continuous variable, was identified as prognostic factor for OS (Hazard ratio = 0.473, 95% confidence interval = 0.359-0.618, P /=1.4 x 10(9)/l experienced superior OS compared with MM patients with an ALC <1.4 x 10(9)/l (65 vs. 26 months, P < 0.0001). Multivariate analysis identified ALC as an independent prognostic factor for OS. This study showed that, in newly diagnosed MM, ALC is an independent prognostic factor for OS, suggesting a significant role of host immune status in the survival of MM.
-
absolute Lymphocyte Count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas
British Journal of Haematology, 2007Co-Authors: Deepti Behl, Svetomir N. Markovic, Kay M Ristow, Thomas E Witzig, Thomas M Habermann, Joseph P Colgan, David J Inwards, William L White, Stephen M Ansell, Ivana N MicallefAbstract:The immunologic mechanisms of action of rituximab include complement mediated lysis and antibody-dependent cellular cytotoxicity. We hypothesised that a stronger host immune system prior to rituximab therapy for follicular (grades 1and 2) lymphomas (FL) would result in better response rates and longer time to progression (TTP). Thus, we studied the role of absolute Lymphocyte Count (ALC) prior to rituximab therapy on treatment efficacy and TTP in FL patients. Between 1996 and 2002, 79 FL patients were treated with single agent rituximab during their lymphoma treatment at the Mayo Clinic. The median age of the cohort was 56.6 years (range: 25-98 years). The median TTP was 12.5 months (range: 1-76 months). Superior TTP was observed with an ALC > or =0.89 x 10(9)/l (n = 40) compared with an ALC or =0.89 x 10(9)/l (23/40, 58%) compared with the ALC <0.89 x 10(9)/l (5/39, 13%) (P < 0.0001). Multivariate analysis showed ALC to be an independent predictor for TTP. This study supports our hypothesis that a higher ALC predicts longer TTP following rituximab therapy.
-
absolute Lymphocyte Count predicts overall survival in follicular lymphomas
British Journal of Haematology, 2006Co-Authors: Mustaqeem Siddiqui, Svetomir N. Markovic, Kay M Ristow, Thomas E Witzig, Thomas M Habermann, Joseph P Colgan, David J Inwards, William L White, Stephen M Ansell, Ivana N MicallefAbstract:Summary The peripheral blood absolute Lymphocyte Count (ALC) recovery after autologous stem cell transplantation has been shown to be an independent prognostic factor for survival for different haematologic malignancies. The role of ALC at diagnosis for follicular (grades 1 and 2) lymphomas (FL) on survival is not well described. The primary objective of this study was to assess the role of ALC on overall survival (OS) in FL patients. Of 1104 FL patients, 228 patients were originally diagnosed, followed, and had all treatment at the Mayo Clinic from 1984 and 1999, were evaluated. The median follow-up was 89 months (range: 8·35–248). ALC as a continuous variable was identified as a predictor for OS [Hazard ratio (HR) = 0·74, P < 0·04]. ALC ≥ 1·0 × 109/l (n = 164) predicted a longer OS versus ALC < 1·0 × 109/l (n = 64; 175 vs. 73 months respectively, P < 0·0001). When compared with the Follicular Lymphoma International Prognostic Index (FLIPI), ALC was an independent prognostic factor for OS by multivariate analysis (HR = 0·677, P < 0·0001). These data suggest a critical role of FL patients’ immune status at diagnosis on survival.
Peter C Wever - One of the best experts on this subject based on the ideXlab platform.
-
the value of the neutrophil Lymphocyte Count ratio in the diagnosis of sepsis in patients admitted to the intensive care unit a retrospective cohort study
PLOS ONE, 2019Co-Authors: Kim Westerdijk, Peter C Wever, Koen S Simons, Marissa Zegers, Peter Pickkers, Cornelis P C De JagerAbstract:Background Early diagnosis and treatment has proven to be of utmost importance in the outcome of sepsis patients. We compared the accuracy of the neutrophil-Lymphocyte Count ratio (NLCR) to conventional inflammatory markers in patients admitted to the Intensive Care Unit (ICU). Methods We performed a retrospective cohort study consisting of 276 ICU patients with sepsis and 388 ICU patients without sepsis. We compared the NLCR as well as C-reactive protein (CRP) level, procalcitonin (PCT) level, white blood cell (WBC) Count, neutrophil Count and Lymphocyte Count on ICU admission between sepsis and non-sepsis ICU patients. To evaluate the sensitivity and specificity, we constructed receiver operating characteristics (ROC) curves. Results Significant differences in NLCR values were observed between sepsis and non-sepsis patients (15.3 [10.8–38.2] (median [interquartile range] vs. 9.3 [6.2–14.5]; P<0.001), as well as for CRP level, PCT level and Lymphocyte Count. The area under the ROC curve (AUROC) of the NLCR was 0.66 (95%CI = 0.62–0.71). AUROC was significantly higher for CRP and PCT level with AUROC’s of 0.89 (95%CI 0.87–0.92) and 0.88 (95%CI 0.86–0.91) respectively. Conclusions The NLCR is less suitable than conventional inflammatory markers CRP and PCT to detect the presence of sepsis in ICU patients. Trial registration ClinicalTrials.gov NCT01274819.
-
predictive value of lymphocytopenia and the neutrophil Lymphocyte Count ratio for severe imported malaria
Malaria Journal, 2013Co-Authors: Marlies E Van Wolfswinkel, Klaske Vliegenthartjongbloed, Mariana De Mendonca Melo, Matthew B B Mccall, Jaap J Van Hellemond, Peter C Wever, Rob Koelewijn, Perry J J Van GenderenAbstract:Background Lymphocytopenia has frequently been described in patients with malaria, but studies on its association with disease severity have yielded conflicting results. The neutrophil/Lymphocyte Count ratio (NLCR) has been introduced as a parameter for systemic inflammation in critically ill patients and was found, together with lymphocytopenia, to be a better predictor of bacteraemia than routine parameters like C-reactive protein and total leukocyte Count. In the present study, the predictive value of the NLCR and lymphocytopenia for severe disease was evaluated in patients with imported malaria.
-
predictive value of lymphocytopenia and the neutrophil Lymphocyte Count ratio for severe imported malaria
Malaria Journal, 2013Co-Authors: Marlies E Van Wolfswinkel, Klaske Vliegenthartjongbloed, Mariana De Mendonca Melo, Matthew B B Mccall, Peter C Wever, Rob Koelewijn, Jaap J Van Hellemond, Perry J J Van GenderenAbstract:Lymphocytopenia has frequently been described in patients with malaria, but studies on its association with disease severity have yielded conflicting results. The neutrophil/Lymphocyte Count ratio (NLCR) has been introduced as a parameter for systemic inflammation in critically ill patients and was found, together with lymphocytopenia, to be a better predictor of bacteraemia than routine parameters like C-reactive protein and total leukocyte Count. In the present study, the predictive value of the NLCR and lymphocytopenia for severe disease was evaluated in patients with imported malaria. All patients diagnosed with malaria at the Harbour Hospital between January 1st 1999 and January 1st 2012 with differential white cell Counts determined within the first 24 hours after admission were included in this retrospective study. Severe malaria was defined according to the WHO criteria. The performance of the NLCR and lymphocytopenia as a marker of severe malarial disease was compared back-to-back with that of C-reactive protein as a reference biomarker. A total of 440 patients (severe falciparum malaria n = 61, non-severe falciparum malaria n = 259, non-falciparum malaria n=120) were included in the study. Lymphocytopenia was present in 52% of all patients and the median NLCR of all patients was 3.2. Total Lymphocyte Counts and NLCR did not differ significantly between groups. A significant correlation of total leukocyte Count and NLCR, but not Lymphocyte Count, with parasitaemia was found. ROC analysis revealed a good negative predictive value but a poor positive predictive value of both lymphocytopenia and NLCR and performance was inferior to that of C-reactive protein. After complete parasite clearance a significant rise in total leukocyte Count and Lymphocyte Count and a significant decrease in NLCR was observed. The NLCR was found to correlate with parasitaemia, but both lymphocytopenia and the NLCR were inferior to C-reactive protein as markers for severe disease in patients with imported malaria. The NLCR and lymphocytopenia are not useful as predictive markers for severe disease in imported malaria in the acute care setting.
-
the neutrophil Lymphocyte Count ratio in patients with community acquired pneumonia
PLOS ONE, 2012Co-Authors: Cornelis P C De Jager, Peter C Wever, Tom Van Der Poll, Eugenie F A Gemen, Ron Kusters, Arianne B Van Gageldonklafeber, Robert J F LaheijAbstract:Study Objective: The neutrophil-Lymphocyte Count ratio (NLCR) has been identified as a predictor of bacteremia in medical emergencies. The aim of this study was to investigate the value of the NLCR in patients with community-acquired pneumonia (CAP). Methods and Results: Consecutive adult patients were prospectively studied. Pneumonia severity (CURB-65 score), clinical characteristics, complications and outcomes were related to the NLCR and compared with C-reactive protein (CRP), neutrophil Count, white blood cell (WBC) Count. The study cohort consisted of 395 patients diagnosed with CAP. The mean age of the patients was 63.4616.0 years. 87.6% (346/395) of the patients required hospital admission, 7.8% (31/395) patients were admitted to the Intensive Care Unit (ICU) and 5.8% (23/395) patients of the study cohort died. The NLCR was increased in all patients, predicted adverse medical outcome and consistently increased as the CURB-65 score advanced. NLCR levels (mean 6 SD) were significantly higher in non-survivors (23.3616.8) than in survivors (13.0611.4). The receiver-operating characteristic (ROC) curve for NLCR predicting mortality showed an area under the curve (AUC) of 0.701. This was better than the AUC for the neutrophil Count, WBC Count, Lymphocyte Count and CRP level (0.681, 0.672, 0.630 and 0.565, respectively). Conclusion: Admission NLCR at the emergency department predicts severity and outcome of CAP with a higher prognostic accuracy as compared with traditional infection markers.
-
lymphocytopenia and neutrophil Lymphocyte Count ratio predict bacteremia better than conventional infection markers in an emergency care unit
Critical Care, 2010Co-Authors: Cornelis P C De Jager, Paul T L Van Wijk, Rejiv B Mathoera, Jacqueline De Jonghleuvenink, Tom Van Der Poll, Peter C WeverAbstract:Introduction Absolute lymphocytopenia has been reported as a predictor of bacteremia in medical emergencies. Likewise, the neutrophil-Lymphocyte Count ratio (NLCR) has been shown a simple promising method to evaluate systemic inflammation in critically ill patients.
